Skip to contentX
Xenetic Biosciences, Inc.
X
XBIOXenetic Biosciences, Inc. Q2 2022 · 10-Q
Revenue$416.71K$416.71K+44.9% vs Q2 2021 Net Income-$2.67M-$2.67MN/M vs Q2 2021 EPS Diluted-$1.90-$1.90N/M vs Q2 2021 Operating Income-$2,687,079N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenetic Biosciences, Inc. · CIK 1534525 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-644.8%−252.7 pt vs Q2 2021
Net margin-641.3%−256.5 pt vs Q2 2021
ended Jun 30, 2022 · filed Aug 11, 2022 · 42 d after period end